secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2022-07-05T23:59:59+00:00
Accession:  0001193125-22-188015
Event type: regulatory
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA plans to reconvene advisory committee for Amylyx's ALS drug AMX0035 on Sept 7
--------------------------------------------------------------------------------

- FDA to reconvene PCNSDAC on September 7, 2022 to discuss AMX0035 NDA for ALS.
- Discussions will focus on additional analyses of clinical data deemed a major amendment to the NDA.
- PDUFA target action date extended to September 29, 2022 from June 29, 2022 for FDA review.
- Advisory committee previously met March 30, 2022; new meeting signals continued FDA scrutiny.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312522188015/0001193125-22-188015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312522188015/d379654d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-188015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer